Personalised Medicine Survey Literacy Survey among Healthcare Professionals

European researchers have been at the forefront of major scientific discoveries in cancer. The undeniable challenge is how best to translate this knowledge and expertise into Personalised Medicine (PM) approaches that improve outcomes and enhance wellbeing for European patients.

The European Alliance for Personalised Medicine (EAPM) recognises that an increased knowledge and understanding of PM and its potential among healthcare professionals is a key enabler for its future integration into European health systems.

In order to increase PM literacy, it is necessary first to determine the current state of understanding of PM and the potential knowledge gaps amongst European healthcare professionals. EAPM proposes the development of a two-step strategy in collaboration with EHA, ESMO, EAU, ESTRO etc to measure the current level of PM literacy among members of your organisation. This will underpin a collaborative approach to increase the knowledge base and appreciation of the key benefits and challenges of PM.

The first step in this process is the evaluation of current levels of PM literacy with a focus group of stakeholders that will include:

Learners which are divided into the following categories:

1 Trainees: physicians in education rto become a medical specialist
2 Intermediate: 1 – 4 years of specialist experience
3 Senior: ≥ 4 years of specialist experience.

The questionnaire is divided into 36 close-ended questions and will take around 20-25 minutes to complete. It will remain completely anonymous.

The second step in this process would be the evaluation of current levels of PM literacy through a quantitative structured series of questions which we propose would be the subject of a voting poll.

For questions/comments, please contact Denis Horgan, EAPM Executive Director at

The results garnered from this poll will be analysed and prepared for scientific publication and will inform the development of a PM education strategy going forward, leading to the production of an educational toolkit that enhances PM knowledge and contributes to the embedding of PM into European health systems.

* 1. Did you complete your specialist training, or are you still in training to become a specialist?
Please choose * only one * of the following:

* 2. What is the date you expect to complete your specialist training and become a specialist? (Year/Month or Year will be sufficient)

Please enter a date :… month/year?

* 3. What is the date you completed your specialist training and became a specialist? (Year/Month or Year will be sufficient)

Please enter a date: … month/year

* 4. How many months did you spend in specialty training?

* 7. What is your date of birth?

Please include:

* 8. What is your gender?

* 10. What are you, or are you training to become, a (double) specialist in?
Please choose *only one* of the following:

* 11. How much time do you currently spend in the following activities? Please
indicate the time you spend as a percentage of your total working time (100%).
Please write your answer(s) here:

* 12. Where are you (primarily) employed?
Please choose *only one* of the following:

* 13. Are you aware of the term ‘Personalised Medicine’ (PM)?

* 14. Are you informed sufficiently about PM so that your clinical practice is up to date?

* 15. Do you feel familiar with issues and advances in PM?

* 16. How important do you consider PM in your clinical practice?

* 17. What do you see as the main barriers to the use of PM?

* 18. Within clinical practice, do you believe that the role of PM will increase or decrease?

* 19. Did you perform or order a genetic/molecular test during 2014?

* 20. If yes, which type of test(s) did you perform or order? (more than one answer is possible)

* 21. Did the decisions you made based on molecular test results improve patient outcomes?

* 22. Do you feels capable enough to make a decision which molecular test to use?

* 23. Do you anticipate ordering a molecular test in the next year?

* 24. To which degree are you able to interpret the results of genetic/molecular tests?

* 25. Do you feel capable discussing molecular tests results with your patients?

* 26. Are you being asked by your patients about genetic/molecular tests or PM?

* 27. Which, if any, of the following sources of information do you use when you have questions about genetic/molecular tests or PM?

* 28. Are guidelines included in Professional Society literature?

* 29. If yes, which best practice guidelines are you aware of:

* 30. Is there enough information available on new treatment options such as personalised medicine nationally?

* 31. Are there currently legal and/or regulatory frameworks for genetic/molecular tests in place?

* 32. Are there currently legal and/or regulatory frameworks for genetic/molecular information in place?

* 33. Are you satisfied with the legal and/or regulatory frameworks in place?

* 34. Did you have formal training in genetic/molecular tests or PM?

* 35. Do you have any suggestion for improving formal training in PM?